QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dajas-Bailador, F. A. Articles by Wonnacott, S. Search for Related Content PubMed PubMed Citation Articles by Dajas-Bailador, F. A. Articles by Wonnacott, S.

The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca²⁺ Signals and Neurotransmitter Release.

Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom

Neuronal nicotinic acetylcholine receptors (nAChR) modulate a variety of cellular responses, including Ca²⁺ signals and neurotransmitter release, which can influence neuronal processes such as synaptic efficacy and neuroprotection. In addition to receptor activation through the agonist binding site, an allosteric modulation of nAChR has also been described for a novel class of allosteric ligands. Of these, the acetylcholinesterase inhibitor and Alzheimer drug galantamine represents the prototypical allosteric ligand, based on its potentiation of nAChR-evoked single-channel and whole-cell currents. The aim of this study was to establish whether the allosteric potentiation of nAChR currents is transduced in downstream cellular responses to nAChR activation, namely increases in intracellular Ca²⁺ and [³H]noradrenaline release. In SH-SY5Y cells, galantamine potentiated nicotine-evoked increases in intracellular Ca²⁺ and [³H]noradrenaline release with a bell-shaped concentration-response profile; maximum enhancement of nicotine-evoked responses occurred at 1 µM galantamine. This potentiation was blocked by mecamylamine, whereas galantamine had no effect on these measures in the absence of nicotine. Galantamine did not compete for radioligand binding to the agonist binding sites of several nAChR subtypes, consistent with an allosteric mode of action. Unlike galantamine, the acetylcholinesterase inhibitors rivastigmine and donepezil did not potentiate nAChR-mediated responses, whereas donepezil was a reasonably potent inhibitor of nicotine- and KCl-evoked increases in Ca²⁺. nAChR-mediated [³H]noradrenaline release from hippocampal slices was also potentiated by galantamine, with an additional component attributable to acetylcholinesterase inhibition and subsequent increase in acetylcholine. These results indicate that the allosteric regulation of nAChR results in the potentiation of receptor-dependent cellular processes relevant to many of the physiological consequences of nAChR activation.

This article has been cited by other articles:

				R. W. Buchanan, R. R. Conley, D. Dickinson, M. P. Ball, S. Feldman, J. M. Gold, and R. P. McMahon Galantamine for the Treatment of Cognitive Impairments in People With Schizophrenia Am J Psychiatry, January 1, 2008; 165(1): 82 - 89. [Abstract] [Full Text] [PDF]

				R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130. [Abstract] [Full Text] [PDF]

				C. Lopes, E. F. R. Pereira, H.-Q. Wu, P. Purushottamachar, V. Njar, R. Schwarcz, and E. X. Albuquerque Competitive Antagonism between the Nicotinic Allosteric Potentiating Ligand Galantamine and Kynurenic Acid at {alpha}7* Nicotinic Receptors J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 48 - 58. [Abstract] [Full Text] [PDF]

				G. Akk and J. H. Steinbach Galantamine Activates Muscle-Type Nicotinic Acetylcholine Receptors without Binding to the Acetylcholine-Binding Site J. Neurosci., February 23, 2005; 25(8): 1992 - 2001. [Abstract] [Full Text] [PDF]

				S. Moriguchi, W. Marszalec, X. Zhao, J. Z. Yeh, and T. Narahashi Mechanism of Action of Galantamine on N-Methyl-D-Aspartate Receptors in Rat Cortical Neurons J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 933 - 942. [Abstract] [Full Text] [PDF]

				L. Zhang, F.-M. Zhou, and J. A. Dani Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release Mol. Pharmacol., September 1, 2004; 66(3): 538 - 544. [Abstract] [Full Text] [PDF]